Navigation Links
Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein
Date:10/28/2009

BAD HOMBURG, Germany and LACHEN, Switzerland, Oct. 28 /PRNewswire/ -- Octapharma Group and Fresenius Kabi have signed a License, Development and Supply Agreement regarding the use of Fresenius Kabi's HESylation® Technology to develop a HESylated recombinant protein.

Under the agreement, Fresenius Kabi will license its proprietary HESylation® Technology to Octapharma. This technology platform is based on hydroxyethyl starch ("HES") which will be combined with a recombinant protein from Octapharma's human cell-line platform -- this combination is intended to generate a therapeutic protein with a superior product profile.

Fresenius Kabi will seek to adapt and optimize the protein modification by its HESylation® Technology and will afterwards be responsible for providing the appropriate HES derivative to Octapharma. Under the agreement, Octapharma will oversee the further development and commercialization. Fresenius Kabi will receive up-front and milestone payments, research funding and royalties on sales for licensing of the HESylation® Technology.

Octapharma's human cell-line platform

Octapharma's core business is the development, production and sale of high quality human protein therapies from both human plasma and human cell lines. Over the last twelve years, Octapharma has successfully established the human HEK293F cell-line platform for the expression of a variety of recombinant therapeutic proteins on a commercial scale.

An investigational new drug application for Octapharma's human cell-line derived recombinant FVIII was filed in the U.S. in May 2008. Using a human cell-line expression system instead of e.g. hamster cell-lines is expected to result in possible advantages like improved protein functions, increased tolerability and the opportunity for reduced immunogenicity.

HESylation® Technology

HESylation® Technology is based on the extensive expertise in the field of hydroxyethyl starch ("HES") that Fresenius Kabi has gathered as the world's largest producer of pharmaceutical grade HES. HES is derived from waxy maize starch and can be metabolized by the body's enzymes. HES solutions have been safely administered for over 30 years to treat deficient blood volume and to improve the rheological properties of blood.

HESylation® Technology allows a targeted modification of drugs and their characteristics by a site-specific coupling to HES molecules. This can modify key pharmacological parameters such as absorption, metabolization, half-life, water solubility and safety.

HESylation® Technology is covered by a broad portfolio of intellectual property rights. For further details please visit http://www.HESylation.com.

About Octapharma Group

The Octapharma Group is an independent, Swiss-based biopharmaceutical company operating worldwide. Octapharma's core business is the development, production, and sale of high-quality human proteins for the treatment of life-threatening diseases.

The Group has more than 3,500 employees in 28 countries, and owns five modern, state-of-the-art production facilities in Austria, France, Germany, Sweden, and Mexico, respectively. Sales turnover in 2008 reached Euro 886 million with an EBIT of Euro 256 million.

For more information about Octapharma Group please visit the company's website: www.octapharma.com

Fresenius Kabi

Fresenius Kabi is focused on products for the therapy and care of critically and chronically ill patients in and outside the hospital. Fresenius Kabi's core product range includes infusion solutions for fluid substitution, blood volume substitution and intravenously administered drugs as well as parenteral and enteral nutrition and the medical devices for the application.

Fresenius Kabi has more than 20,000 employees worldwide and a global network of around 55 sales organizations and more than 55 production sites. In 2008, Fresenius Kabi achieved sales of Euro 2,495 million and an operating profit (EBIT) of Euro 443 million. Fresenius Kabi AG is a 100% subsidiary of the health care group Fresenius SE.

For more information about Fresenius Kabi, please visit the company's web site at www.fresenius-kabi.com.

SOURCE Octapharma


'/>"/>
SOURCE Octapharma
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
2. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
3. Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies
4. Baxter and The Alzheimers Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimers Disease
5. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
6. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
7. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
8. Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups
9. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
10. Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
11. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial ... Company reported second quarter net sales of $1.954 billion, ... and an increase of 2.1% on a constant currency ... the LDR Holding Corporation acquisition, second quarter 2017 revenues ... 0.3% on a constant currency basis. ...
(Date:7/26/2017)... Colo. , July 26, 2017 E.I. ... Guttridge and the Bimini SharkLab to custom design the worlds ... images of sharks in their native habitat. In preparation ... Discovery Channel,s Shark Week, Dr. Guttridge approached EIMI ... take pregnancy diagnosis directly to hammerhead sharks underwater. ...
(Date:7/26/2017)... 26, 2017 Sancilio Pharmaceuticals Company, Inc. (SPCI) ... trial evaluating Altemia TM , an oral therapy for ... Cell Disease (SCD). The SCOT Trial, is a double-blind, ... safety of Altemia TM in pediatric patients aged ... IND 125274. "The ...
Breaking Medicine Technology:
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... The Women’s ... has awarded Zyclear Migraine Relief with the 2017 Women’s Choice Award. The identification by ... show that 3 out of 4 migraine sufferers are women. In a survey taken ...
(Date:8/22/2017)... ... August 22, 2017 , ... ... announce the addition of Zack Tisch as the firm’s new Consulting Services Executive. ... IT consulting firm’s national accounts, from assisting clients with initial vendor selection and ...
(Date:8/22/2017)... , ... August 22, 2017 , ... Nurses at ... at picturesque Babcock Cove, recently received training and certification in Closed Pulse Irrigation™ ... has a prestigious five-star rating from the Centers for Medicare and Medicaid Services, to ...
(Date:8/22/2017)... , ... August 22, 2017 , ... “Wilderness Voices”: a ... world travel. “Wilderness Voices” is the creation of published author, Martha McKown, an ... McKown was inspired as a very young child when her older sisters studied High ...
(Date:8/22/2017)... ... 2017 , ... “Glimpses Of Light”: is a unique and thought inspiring ... the creation of published author, J.M. Shepherd, a writer, teacher, traveler, and metaphysician, the ... mysteries. , Shepherd shares, “Love is one of the least understood and yet most ...
Breaking Medicine News(10 mins):